Brian Taylor Slingsby
At a glance: Brian Taylor Slingsby is Director at Mineralys Therapeutics (MLYS). Their latest SEC Form 4, filed Sep 24, 2026, reported a sale of $3.0M. On file: 0 purchase lines ($0) and 1 sale line ($3.0M).
Disclosed holdings: about $113M of MLYS stock: 7,805,718 shares (including shares held indirectly, e.g. through a trust or fund) reported on their latest Form 4 (filed Sep 24, 2026), valued at the Nov 19, 2026 close of $14.43. This counts only MLYS shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
Director at Mineralys Therapeutics, Inc. (MLYS)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Brian Taylor Slingsby's InsiderPrint
3 trades from SEC Form 4 filings, 2023 to 2026, drawn as one fingerprint.
Reading this print: Mostly buys, trading about once a year, typically $3.5M a trade.
- Bump outward: a purchase (2)
- Dent inward: a sale (1)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Insiders with a similar print
- Bernard Lanigan Jr.Director · CNX · 98% matchTheir buys since 2020: 4 of 5 beat the S&P 500
- Dara KhosrowshahiCEO · UBER · 98% match
- William H. Rogers Jr.CEO, Chair · TFC · 98% match
- William Clay Ford Jr.Chair · F · 97% match
- Michael I. McCabeHead Of Strategy · STEP · 97% match
Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.
Reported trades
Follow Brian Taylor Slingsby
Get one email when Brian Taylor Slingsby files a new purchase or sale. Free.
At most one email a day about Brian Taylor Slingsby, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.